What is Savara Inc.'s earnings per share (EPS)?

Savara Inc. (SVRA) reported diluted earnings per share of -$0.53 for fiscal year 2025. This represents a -10.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Savara Inc. (SVRA) Financials

SVRA

FY2025 annual

Net Income -$118.8M -23.9% YoY

EPS (Diluted) -$0.53 -10.4% YoY

Free Cash Flow -$101.1M -13.4% YoY

Operating Cash Flow -$101.0M -13.4% YoY

Market Cap $914.3M as of Oct 17, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 6.4x on $143.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SVRA SEC filings page.

This page shows Savara Inc. (SVRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SVRA FY2025 2026-10-04

Savara remains a development-stage business: rising research spending and widening cash needs are funded mainly through new financing.

By FY2025, operating cash flow of -$101M nearly matched the net loss of $119M, indicating reported losses were largely cash costs rather than depreciation or working-capital timing. Financing cash inflows reached $138M in FY2025 while operations still consumed cash, showing external capital—not operations—funded the expanding cash requirement.

Research and development reached $81M in FY2025 while selling, general, and administrative spending reached $42M; the company is scaling both scientific work and corporate infrastructure before reporting revenue. The operating loss widened from $103M in FY2024 to $124M in FY2025, so higher spending, not revenue growth, is currently driving the cost base.

Shares outstanding rose from 173M in FY2024 to 205M in FY2025 alongside financing cash inflows, indicating the balance sheet has been supported primarily by equity-oriented funding rather than operating receipts. The reported liquidity comparison was 28 months of the latest annual operating outflow, a historical balance-to-outflow comparison rather than a forecast.

Financial Health Signals

Financial health score not available

Savara Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

Savara Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Savara Inc. reported a net loss of $118.8M while operations used $101.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$40.9M

YoY-30.3%

QoQ-5.1%

Savara Inc.'s EBITDA was -$40.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 30.3% from the same quarter a year earlier. Against the prior quarter it is down 5.1%.

Net Income

-$40.2M

YoY-32.3%

QoQ-7.9%

Savara Inc. reported -$40.2M in net income in Q2 2026. This represents a decrease of 32.3% from the same quarter a year earlier. Against the prior quarter it is down 7.9%.

EPS (Diluted)

-$0.16

YoY-14.3%

QoQ-6.7%

Savara Inc. earned -$0.16 per diluted share (EPS) in Q2 2026. This represents a decrease of 14.3% from the same quarter a year earlier. Against the prior quarter it is down 6.7%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$30.0M

YoY-14.1%

QoQ+9.5%

Savara Inc. recorded an outflow of $30.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 14.1% from the same quarter a year earlier. Against the prior quarter it is up 9.5%.

Cash & Debt

$41.8M

YoY+139.7%

QoQ+7.8%

5Y CAGR+0.6%

10Y CAGR+11.5%

Savara Inc. held $41.8M in cash against $30.1M in long-term debt as of Q2 2026.

Shares Outstanding

205M

YoY+18.9%

QoQ+0.3%

5Y CAGR+12.5%

10Y CAGR-0.3%

Savara Inc. had 205M shares outstanding in Q2 2026. This represents an increase of 18.9% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-28.0%

YoY-2.8pp

QoQ-6.8pp

Savara Inc.'s ROE was -28.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.8 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$22.0M

YoY+5.8%

QoQ-6.2%

Savara Inc. invested $22.0M in research and development in Q2 2026. This represents an increase of 5.8% from the same quarter a year earlier. Against the prior quarter it is down 6.2%.

Capital Expenditures

$222K

YoY+1380.0%

QoQ+311.1%

Savara Inc. invested $222K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1380.0% from the same quarter a year earlier. Against the prior quarter it is up 311.1%.

Share Buybacks

Not reported for Q2 2026.

SVRA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SVRA quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$257K	$0	N/A	$0-100.0%	$400K+640.7%	$54K	$0	$0	$0	N/A
R&D Expenses	N/A	$81.4M+4.3%	$78.0M+76.3%	$44.3M+58.8%	$27.9M-3.8%	$29.0M-17.3%	$35.0M-9.7%	$38.8M+4.3%	$37.2M+100.8%	$18.5M+126.3%	$8.2M+89.4%	$4.3M-77.8%	$19.4M+50.6%	$12.9M+59.5%	$8.1M+40.5%	$5.8M
SG&A Expenses	N/A	$42.1M+68.0%	$25.0M+59.8%	$15.7M+43.4%	$10.9M-11.5%	$12.3M-13.4%	$14.3M+9.0%	$13.1M+22.8%	$10.7M-3.9%	$11.1M+18.6%	$9.3M-14.8%	$11.0M+15.5%	$9.5M+11.4%	$8.5M+13.3%	$7.5M+4.6%	$7.2M
Operating Income	N/A	-$123.5M-19.7%	-$103.2M-72.0%	-$60.0M-54.5%	-$38.8M+6.4%	-$41.5M+15.9%	-$49.3M+37.6%	-$79.0M-12.8%	-$70.0M-133.8%	-$30.0M-173.6%	-$10.9M-84.8%	-$5.9M+79.8%	-$29.3M-35.9%	-$21.5M-37.8%	-$15.6M-16.7%	-$13.4M
EBITDA	N/A	-$123.5M-19.8%	-$103.1M-72.0%	-$59.9M-54.4%	-$38.8M+6.1%	-$41.3M+15.7%	-$49.0M+37.1%	-$78.0M-12.2%	-$69.5M-134.9%	-$29.6M-172.8%	-$10.8M-87.8%	-$5.8M+80.2%	-$29.2M-35.8%	-$21.5M-38.4%	-$15.5M-16.3%	-$13.4M
Interest Expense	N/A	N/A	N/A	N/A	$88K-96.1%	$2.3M+54.0%	$1.5M+2017.1%	$70K	N/A	$1.2M+156.9%	$452K-82.5%	$2.6M	N/A	N/A	N/A	$11K
Income Tax	N/A	$0-100.0%	$9K	N/A	N/A	N/A	N/A	N/A	-$7.1M-94.2%	-$3.6M-917.9%	-$357K	$0	$0	$0	N/A	N/A
Net Income	N/A	-$118.8M-23.9%	-$95.9M-75.3%	-$54.7M-43.4%	-$38.1M+11.3%	-$43.0M+13.3%	-$49.6M+36.5%	-$78.2M-27.1%	-$61.5M-106.5%	-$29.8M-172.8%	-$10.9M-21.4%	-$9.0M+68.6%	-$28.7M-33.6%	-$21.5M-38.1%	-$15.6M-17.3%	-$13.3M
EPS (Basic)	N/A	-$0.53-10.4%	-$0.48-45.5%	-$0.33-32.0%	-$0.25+21.9%	-$0.32	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.58	-$0.53-10.4%	-$0.48-45.5%	-$0.33-32.0%	-$0.25+21.9%	-$0.32	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	222M+12.2%	198M+20.0%	165M+8.1%	153M+14.1%	134M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$22.0M+5.8%	$23.4M+22.1%	N/A	$20.6M+1.4%	$20.8M+17.8%	$19.2M+14.0%	N/A	$20.3M+46.5%
SG&A Expenses	$19.0M+78.2%	$15.6M+68.4%	N/A	$9.6M+60.1%	$10.7M+92.3%	$9.2M+64.1%	N/A	$6.0M+45.0%
Operating Income	-$41.0M-30.3%	-$39.0M-37.1%	N/A	-$30.3M-14.8%	-$31.4M-35.6%	-$28.4M-26.5%	N/A	-$26.4M-46.1%
EBITDA	-$40.9M-30.3%	-$39.0M-37.2%	N/A	-$30.2M-14.8%	-$31.4M-35.6%	-$28.4M-26.6%	N/A	-$26.3M-46.1%
Net Income	-$40.2M-32.3%	-$37.3M-40.0%	N/A	-$29.6M-21.9%	-$30.4M-36.7%	-$26.6M-30.9%	N/A	-$24.2M-46.1%
EPS (Basic)	-$0.16-14.3%	-$0.15-25.0%	-$0.130.0%	-$0.14-27.3%	-$0.14-16.7%	-$0.12-9.1%	-$0.13-44.4%	-$0.11-10.0%
EPS (Diluted)	-$0.16-14.3%	-$0.15-25.0%	-$0.130.0%	-$0.14-27.3%	-$0.14-16.7%	-$0.12-9.1%	-$0.13-44.4%	-$0.11-10.0%
Diluted Shares (Avg)	254M+17.2%	253M+17.2%	N/A	216M+2.2%	216M+18.5%	216M+18.4%	N/A	212M+21.3%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

SVRA Balance Sheet

SVRA quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$253.4M+19.1%	$212.9M+19.9%	$177.6M+27.0%	$139.8M-20.9%	$176.6M+80.7%	$97.7M-28.2%	$136.2M-10.6%	$152.3M-4.6%	$159.6M+451.7%	$28.9M-46.6%	$54.2M-23.1%	$70.5M+27.6%	$55.3M+17.6%	$47.0M-24.1%	$61.9M
Current Assets	$241.6M+19.5%	$202.1M+21.8%	$165.9M+28.7%	$129.0M-21.8%	$165.0M+93.8%	$85.1M-31.4%	$124.1M+9.5%	$113.3M+15.8%	$97.9M+569.7%	$14.6M-65.4%	$42.3M-27.7%	$58.4M+28.3%	$45.5M+22.5%	$37.2M-28.2%	$51.8M
Cash & Equivalents	$33.2M+119.3%	$15.1M-43.1%	$26.6M-49.0%	$52.1M+53.2%	$34.0M+48.7%	$22.9M-54.1%	$49.8M+104.9%	$24.3M+9.9%	$22.1M+65.4%	$13.4M-19.8%	$16.7M+31.5%	$12.7M-50.6%	$25.7M+14.1%	$22.5M-48.4%	$43.6M
Short-Term Investments	$202.5M+11.8%	$181.2M+33.5%	$135.7M+84.0%	$73.8M-42.0%	$127.2M+114.4%	$59.3M-17.6%	$72.0M-16.8%	$86.5M+19.9%	$72.2M	$0	$0	$0	$0-100.0%	$14.0M+96.4%	$7.1M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$2.7M-42.6%	$4.7M+62.1%	$2.9M	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	$0	N/A	$26.9M-0.6%	$27.1M+787.6%	$3.1M+1.5%	$3.0M0.0%	$3.0M0.0%	$3.0M0.0%	$3.0M0.0%	$3.0M
Total Liabilities	$50.3M+21.4%	$41.4M+11.4%	$37.2M+16.2%	$32.0M-0.3%	$32.1M-3.8%	$33.4M-3.3%	$34.5M-21.7%	$44.1M+9.3%	$40.3M-37.8%	$64.8M-20.5%	$81.5M-8.2%	$88.8M+1093.2%	$7.4M+43.7%	$5.2M+2.0%	$5.1M
Current Liabilities	$20.4M+38.5%	$14.7M+38.9%	$10.6M+80.6%	$5.9M-60.0%	$14.7M+79.3%	$8.2M-24.9%	$10.9M+50.0%	$7.3M+20.6%	$6.0M+74.1%	$3.5M-85.1%	$23.2M+174.6%	$8.4M+74.6%	$4.8M+88.0%	$2.6M+4.1%	$2.5M
Non-Current Liabilities	$29.9M+12.0%	$26.7M+0.4%	$26.6M+1.8%	$26.1M+49.8%	$17.4M-30.8%	$25.2M+6.6%	$23.6M-35.8%	$36.8M+7.3%	$34.3M-44.1%	$61.4M+5.1%	$58.4M-27.4%	$80.4M+2980.1%	$2.6M0.0%	$2.6M0.0%	$2.6M
Long-Term Debt	$29.9M+12.4%	$26.6M+1.0%	$26.3M+1.0%	$26.1M+50.5%	$17.3M-31.0%	$25.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$203.1M+18.5%	$171.4M+22.1%	$140.4M+30.2%	$107.8M-25.4%	$144.5M+124.4%	$64.4M-36.7%	$101.7M-6.0%	$108.2M-9.3%	$119.3M+432.6%	-$35.9M-31.3%	-$27.3M-49.3%	-$18.3M-138.3%	$47.8M+14.4%	$41.8M-26.4%	$56.8M
Retained Earnings	-$608.1M-24.3%	-$489.3M-24.4%	-$393.4M-16.2%	-$338.7M-12.7%	-$300.5M-16.7%	-$257.5M-23.9%	-$207.9M-60.3%	-$129.7M-90.2%	-$68.2M-77.6%	-$38.4M+86.0%	-$275.0M-16.9%	-$235.1M-13.9%	-$206.4M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$192.1M+17.3%	$221.6M+17.1%	$253.4M+19.1%	$140.9M-41.0%	$163.8M+17.3%	$189.3M+19.6%	$212.9M+19.9%	$238.8M+31.2%
Current Assets	$178.3M+18.1%	$209.3M+17.9%	$241.6M+19.5%	$128.2M-43.4%	$151.0M+18.2%	$177.4M+21.4%	$202.1M+21.8%	$226.4M+33.1%
Cash & Equivalents	$41.8M+139.7%	$38.8M+98.4%	$33.2M+119.3%	$16.3M-24.0%	$17.4M-26.9%	$19.6M+16.5%	$15.1M-43.1%	$21.4M-22.6%
Short-Term Investments	$131.2M+1.7%	$164.0M+7.2%	$202.5M+11.8%	$108.1M-45.4%	$129.0M+32.1%	$152.9M+21.1%	$181.2M+33.5%	$198.0M+40.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$48.5M+12.0%	$45.6M+10.0%	$50.3M+21.4%	$46.5M+17.9%	$43.3M+14.1%	$41.5M+13.8%	$41.4M+11.4%	$39.5M+11.1%
Current Liabilities	$17.6M+29.1%	$15.5M+30.6%	$20.4M+38.5%	$16.8M+31.0%	$13.6M+20.8%	$11.9M+21.3%	$14.7M+38.9%	$12.8M+42.7%
Non-Current Liabilities	$30.9M+4.1%	$30.1M+1.7%	$29.9M+12.0%	$29.8M+11.6%	$29.7M+11.3%	$29.6M+11.1%	$26.7M+0.4%	$26.7M+0.4%
Long-Term Debt	$30.1M+1.5%	$30.1M+1.8%	$29.9M+12.4%	$29.8M+12.2%	$29.7M+12.0%	$29.5M+11.8%	$26.6M+1.0%	$26.6M+1.0%
Total Equity	$143.7M+19.2%	$176.0M+19.1%	$203.1M+18.5%	$94.4M-52.7%	$120.5M+18.4%	$147.8M+21.3%	$171.4M+22.1%	$199.3M+36.0%
Retained Earnings	-$685.6M-25.5%	-$645.4M-25.1%	-$608.1M-24.3%	-$575.9M-25.1%	-$546.3M-25.3%	-$515.9M-24.7%	-$489.3M-24.4%	-$460.2M-22.0%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

SVRA Cash Flow Statement

SVRA quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$110.4M	-$101.0M-13.4%	-$89.1M-74.5%	-$51.1M-47.8%	-$34.6M+13.8%	-$40.1M-0.6%	-$39.8M+11.7%	-$45.1M-14.9%	-$39.3M-39.1%	-$28.2M-237.3%	-$8.4M-75.2%	-$4.8M+80.6%	-$24.6M-38.5%	-$17.8M-27.8%	-$13.9M-3.4%	-$13.5M
Depreciation & Amortization	N/A	$87K-33.1%	$130K+68.8%	$77K+148.4%	$31K-77.2%	$136K-46.7%	$255K-74.8%	$1.0M+92.0%	$526K+44.9%	$363K+266.7%	$99K-32.2%	$146K+71.8%	$85K+115.1%	$40K-56.1%	$90K+139.7%	$38K
Stock-Based Compensation	N/A	$14.4M+46.3%	$9.9M+136.0%	$4.2M+104.7%	$2.0M-37.4%	$3.3M-36.2%	$5.1M+15.0%	$4.4M+18.8%	$3.7M+577.0%	$552K+164.1%	$209K+36.6%	$153K-92.5%	$2.0M+27.0%	$1.6M+9.6%	$1.5M+68.5%	$866K
Capital Expenditures	$280K	$22K-12.0%	$25K-91.6%	$296K+3188.9%	$9K-84.2%	$57K+21.3%	$47K-68.2%	$148K+5.0%	$141K-71.5%	$495K+6087.5%	$8K-95.2%	$165K+12.2%	$147K+212.8%	$47K-82.3%	$266K-35.4%	$412K
Free Cash Flow	-$110.7M	-$101.1M-13.4%	-$89.1M-73.5%	-$51.4M-48.6%	-$34.6M+13.9%	-$40.1M-0.6%	-$39.9M+11.9%	-$45.3M-14.9%	-$39.4M-37.2%	-$28.7M-242.9%	-$8.4M-69.5%	-$4.9M+80.1%	-$24.8M-39.0%	-$17.8M-25.7%	-$14.2M-2.2%	-$13.9M
Investing Cash Flow	-$721K	-$18.4M+53.8%	-$39.9M+30.1%	-$57.1M-208.5%	$52.6M+175.8%	-$69.5M-867.2%	$9.1M-42.5%	$15.7M+215.6%	-$13.6M+80.3%	-$69.1M	N/A	N/A	N/A	-$4.8M+33.5%	-$7.2M+5.0%	-$7.5M
Financing Cash Flow	$135.5M	$137.8M+17.2%	$117.6M+42.0%	$82.8M+95049.4%	$87K-99.9%	$120.8M+3174.8%	$3.7M-93.3%	$54.9M-0.5%	$55.2M-48.0%	$106.1M	N/A	N/A	N/A	$25.7M+3477866.5%	$740-100.0%	$36.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$29.7M-13.3%	-$33.0M-21.5%	-$25.1M-7.6%	-$22.5M+0.6%	-$26.3M-16.7%	-$27.2M-31.7%	-$23.3M-49.2%	-$22.7M-72.2%
Depreciation & Amortization	$28K-17.6%	$24K-20.0%	N/A	$36K+9.1%	$34K+3.0%	$30K-6.3%	N/A	$33K+10.0%
Stock-Based Compensation	$7.8M+190.9%	$10.7M+260.9%	N/A	$3.4M+44.5%	$2.7M+21.5%	$3.0M+31.7%	N/A	$2.4M+138.3%
Capital Expenditures	$222K+1380.0%	$54K+1700.0%	$2K-77.8%	$2K-33.3%	$15K-28.6%	$3K-70.0%	-$9K-62.5%	$3K-93.0%
Free Cash Flow	-$30.0M-14.1%	-$33.1M-21.7%	-$25.1M-7.6%	-$22.5M+0.6%	-$26.3M-16.7%	-$27.2M-31.7%	-$23.3M-49.0%	-$22.7M-71.7%
Investing Cash Flow	$32.6M+34.0%	$38.8M+32.2%	-$93.6M-622.8%	$21.5M+121.9%	$24.3M-17.6%	$29.3M+171.7%	$17.9M+172.3%	-$98.2M-73.5%
Financing Cash Flow	$189K+485.7%	-$195K-108.4%	$135.6M+16180.7%	-$23K-100.0%	-$49K-189.1%	$2.3M+4630.6%	-$843K-110.7%	$118.3M+58.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SVRA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SVRA quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	-19182.9%	N/A	N/A	N/A	-2737.0%	-10968.5%	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-19305.5%	N/A	N/A	N/A	-2730.8%	-16664.8%	N/A	N/A	N/A	N/A
Return on Equity	-58.5%-2.6pp	-55.9%-17.0pp	-39.0%-3.6pp	-35.4%-5.6pp	-29.8%+47.3pp	-77.1%-0.2pp	-76.9%-20.0pp	-56.8%-31.9pp	-25.0%	N/A	N/A	N/A	-44.9%-7.7pp	-37.2%-13.9pp	-23.4%
Return on Assets	-46.9%-1.8pp	-45.0%-14.2pp	-30.8%-3.5pp	-27.3%-2.9pp	-24.4%+26.4pp	-50.8%+6.6pp	-57.4%-17.0pp	-40.4%-21.7pp	-18.7%+19.1pp	-37.8%-21.1pp	-16.6%+24.1pp	-40.7%-1.8pp	-38.9%-5.8pp	-33.1%-11.7pp	-21.4%
Current Ratio	11.85-1.9x	13.73-1.9x	15.66-6.3x	21.98+10.7x	11.26+0.8x	10.41-1.0x	11.40-4.2x	15.63-0.6x	16.27+12.0x	4.23+2.4x	1.82-5.1x	6.92-2.5x	9.42-5.0x	14.46-6.5x	20.98
Debt-to-Equity	0.150.0x	0.160.0x	0.19-0.1x	0.24+0.1x	0.12-0.3x	0.39+0.1x	0.34-0.1x	0.41+0.1x	0.34	N/A	N/A	N/A	0.160.0x	0.120.0x	0.09
Asset Turnover	N/A	N/A	N/A	N/A	N/A	0.000.0x	0.00	N/A	0.000.0x	0.010.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	-15518.7%	N/A	N/A	N/A	-2094.5%	-9153.7%	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-28.0%-2.8pp	-21.2%-3.2pp	N/A	-31.3%-19.2pp	-25.2%-3.4pp	-18.0%-1.3pp	N/A	-12.2%-0.8pp
Return on Assets	-20.9%-2.4pp	-16.8%-2.7pp	N/A	-21.0%-10.8pp	-18.6%-2.6pp	-14.1%-1.2pp	N/A	-10.2%-1.0pp
Current Ratio	10.13-0.9x	13.47-1.4x	11.85-1.9x	7.65-10.1x	11.08-0.2x	14.910.0x	13.73-1.9x	17.70-1.3x
Debt-to-Equity	0.210.0x	0.170.0x	0.150.0x	0.32+0.2x	0.250.0x	0.200.0x	0.160.0x	0.130.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Savara Inc. SVRA	FY2025	N/A	-$118.8M	N/A	$914.3M	—
Palvella Therapeutics, Inc. PVLA	FY2025	N/A	-$41.7M	N/A	$1.7B	—
Oruka Therapeutics, Inc. ORKA	FY2025	N/A	-$105.4M	N/A	$4.8B	—
AnaptysBio, Inc. ANAB	FY2025	$234.6M	-$13.2M	-5.6%	$1.4B	80/100
Septerna, Inc. SEPN	FY2025	$46.0M	-$48.9M	N/A	$1.7B	47/100
Keros Therapeutics, Inc. KROS	FY2025	$243.9M	$87.0M	35.7%	$211.4M	91/100

Where Savara Inc. Ranks

Frequently Asked Questions

Is Savara Inc. profitable?

No, Savara Inc. (SVRA) reported a net income of -$118.8M in fiscal year 2025.

What is Savara Inc.'s EBITDA?

Savara Inc. (SVRA) had EBITDA of -$123.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Savara Inc. have?

As of fiscal year 2025, Savara Inc. (SVRA) had $33.2M in cash and equivalents against $29.9M in long-term debt.

What is Savara Inc.'s return on equity (ROE)?

Savara Inc. (SVRA) has a return on equity of -58.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Savara Inc.'s free cash flow?

Savara Inc. (SVRA) recorded an outflow of $101.1M in free cash flow during fiscal year 2025. This represents a -13.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Savara Inc.'s operating cash flow?

Savara Inc. (SVRA) recorded an outflow of $101.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Savara Inc.'s total assets?

Savara Inc. (SVRA) had $253.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Savara Inc.'s capital expenditures?

Savara Inc. (SVRA) invested $22K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Savara Inc. spend on research and development?

Savara Inc. (SVRA) invested $81.4M in research and development during fiscal year 2025.

How many shares does Savara Inc. have outstanding?

Savara Inc. (SVRA) had 205M shares outstanding as of fiscal year 2025.

What is Savara Inc.'s current ratio?

Savara Inc. (SVRA) had a current ratio of 11.85 as of fiscal year 2025, which is generally considered healthy.

What is Savara Inc.'s debt-to-equity ratio?

Savara Inc. (SVRA) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Savara Inc.'s return on assets (ROA)?

Savara Inc. (SVRA) had a return on assets of -46.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Savara Inc.'s P/E ratio?

Savara Inc. (SVRA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $914.3M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Savara Inc.'s price-to-sales ratio?

Savara Inc. (SVRA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $914.3M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Savara Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Savara Inc. (SVRA) held $235.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $101.0M over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Savara Inc.'s Piotroski F-Score?

Savara Inc. (SVRA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Savara Inc.'s earnings high quality?

Savara Inc. (SVRA) reported a net loss of $118.8M while operations used $101.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.